| |
Females
|
Males
|
Unadjusted OR (95 % CI)
|
Adjusted ORa (95 % CI)
|
|---|
| |
Number
|
Percent
|
Number
|
Percent
| | |
|---|
|
Totalb
|
3750
| |
326
| | | |
|
Morphology
|
|
Ductal carcinoma
|
2693
|
83.6
|
253
|
95.1
|
Reference
|
Reference
|
|
Lobular carcinoma
|
276
|
8.6
|
4
|
1.5
|
0.15 (0.06–0.41)
|
0.14 (0.05–0.43)
|
|
Medullary carcinoma
|
60
|
1.9
|
2
|
0.8
|
0.35 (0.09–1.46)
|
0.46 (0.10–2.11)
|
|
Other
|
193
|
6.0
|
7
|
2.6
|
0.39 (0.18–0.83)
|
0.54 (0.24–1.23)
|
|
TNM stage
|
|
0–1
|
560
|
40.2
|
44
|
29.5
|
Reference
|
Reference
|
|
2
|
629
|
45.1
|
70
|
47.0
|
1.42 (0.95–2.10)
|
1.97 (1.20–3.23)
|
|
3–4
|
205
|
14.7
|
35
|
23.5
|
2.17 (1.37–3.44)
|
3.55 (1.96–6.44)
|
|
Histologic grade
|
|
Grade 1
|
149
|
5.9
|
8
|
3.5
|
Reference
|
Reference
|
|
Grade 2
|
1057
|
41.7
|
92
|
39.8
|
1.62 (0.77–3.41)
|
1.88 (0.76–4.67)
|
|
Grade 3
|
1329
|
52.4
|
131
|
56.7
|
1.84 (0.88–3.83
|
2.66 (1.08–6.55)
|
|
Lymph node status
|
|
Negative
|
1398
|
52.4
|
123
|
50.2
|
Reference
|
Reference
|
|
Positive
|
1270
|
47.6
|
122
|
49.8
|
1.09 (0.84–1.43)
|
1.55 (1.12–2.14)
|
|
ER status
|
|
Negative
|
650
|
22.7
|
8
|
3.3
|
Reference
|
Reference
|
|
Positive
|
2211
|
77.3
|
236
|
96.7
|
8.67 (4.26–17.66)
|
10.59 (5.15–21.80)
|
|
PR status
|
|
Negative
|
892
|
35.0
|
30
|
13.2
|
Reference
|
Reference
|
|
Positive
|
1654
|
65.0
|
198
|
86.8
|
3.56 (2.41–5.26)
|
5.04 (3.17–8.04)
|
|
HER2 status
|
|
Negative
|
1404
|
85.9
|
126
|
83.4
|
Reference
|
Reference
|
|
Positive
|
230
|
14.1
|
25
|
16.6
|
1.21 (0.77–1.90)
|
1.22 (0.70–2.11)
|
|
Subtypes
|
|
ER+ and/or PR+, HER2−
|
1112
|
69.8
|
118
|
81.9
|
Reference
|
Reference
|
|
ER+ and/or PR+, HER2+
|
182
|
11.4
|
22
|
15.3
|
1.14 (0.70–1.84)
|
1.18 (0.65–2.13)
|
|
ER−, PR−, HER2+
|
40
|
2.5
|
2
|
1.4
|
0.47 (0.11–1.98)
|
0.42 (0.09–1.98)
|
|
Triple-negative (ER−, PR−, HER2−)
|
260
|
16.3
|
2
|
1.4
|
0.07 (0.02–0.30)
|
0.05 (0.01–0.22)
|
|
ER+ and/or PR+, HER2− vs. others
| | | | |
0.51 (0.33–0.79)
|
0.42 (0.25–0.70)
|
-
BRCA2 breast cancer 2, early onset gene, CI confidence interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio, PR progesterone receptor, TNM tumour, node, metastasis
- Significant results are indicated by boldface type
-
aAnalyses adjusted for country, age at diagnosis and calendar year of diagnosis
-
bSome data for each pathologic feature are not available
